TickerGuard
Buy Day today: Neutral (60) Mixed market breadth · no major macro event
MYGN

Myriad Genetics Inc

Healthcare · Diagnostics & Research

4.00$ +0.2% vs. previous close Closing price · As of: Sep 22, 2026

Statements

Income Statement

All figures as a percentage of revenue in the same period.

Tick rows to compare them in a chart (up to 4)

Income Statement MYGN
Line item 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0%
14.0% 20.4% 21.2% 23.5% 23.8% 23.6% 32.0% 28.6% 29.8% 31.4% 30.1% 30.1%
86.0% 79.6% 78.8% 76.5% 76.2% 76.4% 68.0% 71.4% 70.2% 68.6% 69.9% 69.9%
8.7% 10.4% 9.5% 10.2% 9.5% 10.1% 14.5% 11.9% 12.6% 11.8% 13.5% 13.0%
42.0% 65.4% 91.1% 77.9% 36.5% 37.7% 32.9% 31.1%
50.7% 61.1% 58.0% 70.5% 59.8% 75.5% 117.3% 99.0% 88.5% 87.8% 80.4% 78.2%
35.3% 18.6% 20.7% 6.0% 16.4% 0.9% -35.0% -27.6% -18.2% -19.2% -10.5% -8.2%
0.0% 0.0% 0.0% 0.8% 0.4% 1.4% 1.9% 1.0% 0.5% 0.4% 0.3% 1.3%
35.7% 18.7% 21.1% 5.0% 16.1% 0.9% -50.9% -8.3% -20.7% -34.8% -14.7% -47.9%
13.1% 7.6% 5.2% 2.6% -1.7% -0.5% -10.8% -4.3% -4.2% 0.1% 0.5% -3.5%
22.6% 11.1% 15.8% 2.4% 17.9% 0.5% -40.2% -3.9% -16.5% -35.0% -15.2% -44.4%
37.0% 22.1% 24.7% 12.4% 23.9% 10.0% -22.2% 1.8% -12.5% -26.2% -7.1% -40.1%

Data as of: September 22, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?